Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Official record

Identifier

NCT07562152

Recruiting locations

countries

United StatesAustraliaGeorgiaUnited Kingdom

Interventions studied

AtebimetinibGnPmGnP

Lead sponsor

Immuneering Corporation

Target enrolment

510 participants

Study type

INTERVENTIONAL

Phase

Phase 3

Status

Recruiting

First posted

May 1, 2026

Last updated on the registry

Sep 25, 2026

Age

18 Years

Sex

ALL

Study contact

The official record lists a study contact. Contact details are published there and are intentionally not copied to this page.

Eligibility criteria

Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.

Inclusion Criteria:

* Must be ≥18 years of age
* Must have confirmed diagnosis according to AJCC staging as follows:

  * Metastatic pancreatic adenocarcinoma within 12 weeks prior to screening
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
* Participants must be treatment naive as follows:

  * First-line PDAC participants will have received no previous systemic anti-cancer therapy
* Must have evidence of measurable disease (at least one target lesion) per RECIST v1.1 criteria
* Adequate organ function, hepatic function, coagulation studies and protocol determined clinical laboratory values

Exclusion Criteria:

* Inability to swallow oral medications
* Participant has squamous, adenosquamous, neuroendocrine (carcinoid, islet cell) or acinar pancreatic carcinoma
* Participants with only locally advanced disease
* Symptomatic, untreated, or actively progressing known central nervous system (CNS) metastases

Indexed under

Pancreatic Cancer